Agonista del receptor de trombopoyetina como tratamiento de trombocitopenia asociada a lupus eritematoso sistémico

Moreno Martínez, María José; Gallego, Pilar; Moreno Ramos, Manuel J.
Reumatol. clín. (Barc.) ; 12(1): 57-57, ene.-feb. 2016.
Artículo en Español | IBECS (España) | ID: ibc-149363

Documentos relacionados

  1. Getting an aMPLe grasp on hematopoiesis.
  2. Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis.
  3. Hereditary thrombocythemia due to splicing donor site mutation of THPO in a Japanese family.
  4. Treatment of severe thrombocytopenia associated with systemic lupus erythematosus in pregnancy with eltrombopag: A case report and literature review.
  5. Notch1 regulates hepatic thrombopoietin production.
  6. Thrombopoietin maintains cell numbers of hematopoietic stem and progenitor cells with megakaryopoietic potential.
  7. Repeat dose and reproductive toxicity of thrombopoietin mimic peptide in Sprague-Dawley rats.
  8. Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non-inferiority, randomized controlled trial.
  9. To Clot or Not to Clot: Deepening Our Understanding of Alterations in the Hemostatic System.
  10. [Effect of artificial liver with double plasma molecular absorb system model on patients' platelets and corresponding treatment strategy].